Post-earnings recap
Reported
Thu, Feb 10, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may indicate uncertainty about future performance. Investors may be cautious as the company navigates its financial challenges while focusing on research and development.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.69 | N/A | -14.89% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance while reaffirming their commitment to long-term growth. They acknowledged the difficulties faced in the quarter.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in R&D despite losses.